MBQ Pharma anti-metastatic cancer therapies block and prevent metastasis and tumor growth by targeting and inhibiting the Rac/Cdc42 GTPases. Our lead candidate, MBQ-167, is currently the most efficient Rac1 and Cdc42 inhibitor available for research, showing non-clinical efficacy evidence in triple negative breast cancer, HER2 positive trastuzumab-resistant breast cancer, and stomach cancer. We are currently conducting further preclinical studies of MBQ-167 towards Investigational New Drug FDA submission.
Contact
MBQ Pharma, Inc.
PO Box 19616,
San Juan, PR 00910
mbqpharma.com